This systematic review evaluated the effects of DPP-4 inhibitors on glycemic control (HbA1c and TIR) and pancreatic insulin reserve (C-peptide) in patients with T1DM, based on five selected studies [13,17,18,19,23]. Here, DPP4 is linked to type 1 diabetes mellitus.